CIK 0001570562
- Accelerated filer
Evolus, Inc.
Sign in to watch- Ticker
- EOLS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 461385614
- Phone
- +1 949-284-4555
- Business address
- 520 NEWPORT CENTER DRIVE, SUITE 1200, NEWPORT BEACH, CA, 92660
- Former names
- Evolus, Inc.
- 4 Planned sale Chief Financial Officer sold 1,821 shares at $13.08 ($23,821)
- 4 Grant or award Director acquired 6,464 shares (grant or award)
- 4 Grant or award Director acquired 6,464 shares (grant or award)
- 4 Grant or award Director acquired 6,464 shares (grant or award)
- 4 Grant or award Director acquired 6,464 shares (grant or award)
- 4 Grant or award Director acquired 6,464 shares (grant or award)
- 4 Grant or award Director acquired 6,464 shares (grant or award)
- 4 Grant or award Chief Marketing Officer acquired 24,648 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 35,211 shares (grant or award)
- 4 Grant or award See Remarks acquired 35,211 shares (grant or award)
- 4 Grant or award See Remarks acquired 134,976 shares (grant or award)
- 4 Planned sale Director sold 11,931 shares at $13.14 ($156,733)
- 4 Open-market sale See Remarks sold 82,648 shares at an average $9.95 ($822,396)
- 4 Open-market sale Former 10% Owner sold 1,690,663 shares at $7.50 ($12,679,973)
- 4 Planned sale Chief Financial Officer sold 3,178 shares at $9.70 ($30,827)
- 4 Grant or award Chief Marketing Officer acquired 63,358 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Planned sale See Remarks sold 2,211 shares at $10.27 ($22,707)
- 4 Planned sale Chief Financial Officer sold 2,211 shares at $10.27 ($22,707)
- 4 Planned sale See Remarks sold 14,778 shares at $10.27 ($151,770)
Page 4 of 13 · 252 filings